← Feed

u/stockratic

3 theses · first seen Aug 21, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d000———
3d1100%-3.1%-3.1%
1w1100%-0.3%-0.3%
1m1100%-6.7%-6.7%
3m000———
6m000———
1y000———

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$NRXPr/pennystocksDDbullish
u/stockratic · 34h ago2 prior · awaiting results

NRx Pharmaceuticals (NRXP) - Great news again! Today's PR is essentially final confirmation needed for an FDA approval letter on "OR PRIOR TO" the FDA's Nov 10 GDUFA decision date for the KETAFREE ANDA.

NRx Pharmaceuticals is on track for FDA approval of KETAFREE (preservative-free ketamine ANDA) by Nov 10, 2026 GDUFA date with manufacturing validation complete and commercial supply ready. Approval will address a drug shortage, enabling rapid market entry, formulary placement, and potential short squeeze (24% shares shorted), with near-term price target of $10 and upside to $45-50 based on pipeline catalysts.

At post $2.63Now $3.51+33.5% since postedas of Aug 24, 1:28 PM ET
original post →
$NRXPr/pennystocksDDbullish
u/stockratic · 5d ago2 prior · awaiting results

NRx Pharmaceuticals (NRXP) - NOV 10 is the GDUFA date! Yesterday they announced receipt of a letter from the FDA stating that only a product labeling correction is needed. Great news! NRXP is on track for approval and their drug is now as highly derisked as you can get.

NRXP's KETAFREE ketamine product has achieved FDA de-risking with only labeling corrections required before the November 10 GDUFA approval date. The company will be the sole US-manufactured, preservative-free ketamine supplier with 4-5M vials ready to ship, positioning it to capture significant share in a $3B ketamine/esketamine market while addressing chronic US supply shortages.

At post $2.60Now $3.51+35.0% since postedas of Aug 24, 1:28 PM ET
original post →
$NRXPr/pennystocksDDbullish
u/stockratic · 60d ago2 prior · awaiting results

NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.

NRx Pharmaceuticals is positioned for near-term FDA approval of KETAFREE (preservative-free ketamine), addressing critical supply chain and safety issues while solving strategic FDA goals. The company has resolved the only outstanding FDA concern (luer lock vial attestation) and has significant pre-launch commercialization momentum, with share price expected to respond positively to ANDA approval and subsequent NDA filings.

At post $3.56Now $3.51-1.4% since postedas of Aug 24, 1:28 PM ET
1d—
3d-3.1%
1w-0.3%
1m-6.7%
3m—
6m—
1y—
original post →

End of results.